CAJ | 학술논문

目的观察恩度(重组人血管内皮抑制素)联合周剂量多西紫杉醇治疗70岁以上老年非小细胞肺癌的近期临床疗效及毒副反应.方法试验组恩度+周剂量多西紫杉醇和对照组单用多西紫杉醇周剂量方案治疗老年性非小细胞肺癌60例,2～4周期,按照REClST标准和NCI-CTC标准分别评价两组的疗效和毒副反应.结果试验组有效率66.6%,疾病控制率86.6%;对照组有效率36.6%,疾病控制率56.6%,近期毒副反应有骨髓抑制白细胞减少、血小板减少、纳差、乏力、肌肉关节酸痛等.结论恩度联合周剂量多西紫杉醇治疗老年性非小细胞肺癌近期疗效较高,毒副反应轻,安全性好.
목적 관찰은도(중조인혈관내피억제소)연합주제량다서자삼순치료70세이상노년비소세포폐암적근기림상료효급독부반응.방법 시험조은도+주제량다서자삼순화대조조단용다서자삼순주제량방안치료노년성비소세포폐암60례,2～4주기,안조REClST표준화NCI-CTC표준분별평개량조적료효화독부반응.결과 시험조유효솔66.6%,질병공제솔86.6%;대조조유효솔36.6%,질병공제솔56.6%,근기독부반응유골수억제백세포감소、혈소판감소、납차、핍력、기육관절산통등.결론 은도연합주제량다서자삼순치료노년성비소세포폐암근기료효교고,독부반응경,안전성호.
Objective To observe the short-term efficacy and safety of rh-endostain (endostar) combined with weekly does of Doeetsxd regimen in patients with advanced non-small cell lung cancer of aged person for up to 70 years old. Methods Sixty patients with stage Ⅲ b-Ⅳ NSCLC of aged person were divided into weekly does of Do-cetaxd adding endostar group (trial group) and weekly does of Docetaxd(contral group), the efficacy and toxicity were evaluated after two-four cycles according to RECIST and NC1-CTC criteria. Results The effective rate was 66.6% in trial group and 36.6% in contral group. The disease contral rate was 86.6% in trial group and 56.6% in contral group The short-term toxicity effects were neutropenia, thrombocytopenia, anorexia, hypodynamia, muscular sore-ness, et al. Conclusions Endostar combined with weekly dose of Docetaxd regimen is effective , and the toxicity is tol-erable.